<DOC>
	<DOCNO>NCT02357420</DOCNO>
	<brief_summary>The purpose study evaluate effect multiple dose regimen RM-131 vomit episode , gastric empty gastroparesis symptom patient Type 1 Type 2 diabetes mellitus gastroparesis . Study drug ( RM-131 placebo ) administer subcutaneously blind fashion .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy RM-131 Administered Patients With Vomiting Symptoms Moderate Severe Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<criteria>T1DM T2DM stable glycemic control HbA1c ≤11 % screening . DG , define least 3month history symptom suggestive gastroparesis ongoing basis ( e.g. , vomit , nausea , early satiety , bloating , epigastric abdominal pain ) . Gastroparesis Cardinal Symptom Index Daily Diary ( GCSIDD ) score ≥2.6 least Screening Period ( Visits 12 ) . At least 2 vomit episode ~2 week prior first screen visit ( Visit 1 ) , ascertain patient history . Delayed GE confirm screen abnormal Gastric Emptying Breath Test ( GEBT ) , define GE halftime ( t1/2 ) ≥79 minute ( 80th percentile normative data ) . At least 50 % patient enrol t1/2 ≥97 minute ( i.e. , 95th percentile ) . Stable concomitant medication , define change regimen least 2 week prior Visit 2 ( daily adjustment insulin dos permit ) . No use metoclopramide , erythromycin , domperidone , GI motility agent , antiemetic least 2 week prior Visit 2 , willingness remain medication ( except use part protocolspecific rescue medication ) course clinical trial . Body mass index &gt; 18 kg/m2 . If female , negative serum urine pregnancy test lactating . For female able bear child , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method , doublebarrier method birth control must use throughout study . Female patient unable bear child must document electronic case report form ( eCRF ) ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum 1 year since last menstrual period ] ) . Postmenopausal status confirm measurement follicle stimulate hormone ( FSH ) . Able provide write informed consent prior study procedure willing able comply study procedure . Additional inclusion criterion randomization 2week singleblind placebo runin period : Compliance completion DGSSD study drug injection , define approximately 80 % diary completion approximately 80 % administration injection , 2week singleblind placebo runin period . For patient whose compliance measure &lt; 80 % , final decision randomize patient make Investigator Sponsor ( designee ) . At least one vomit episode time 2week singleblind placebo runin period , record DGSSD . Currently receive parenteral feed presence nasogastric enteral tube [ e.g. , PEG ( percutaneous endoscopic gastrostomy ) tube ] feed decompression . History gastric surgery fundoplication , gastrectomy , gastric pacemaker placement , vagotomy , bariatric procedure . ( A history diagnostic endoscopy exclusionary . ) History pyloric injection botulinum toxin within 6 month screen . Patients clinical suspicion upper gastrointestinal ( GI ) obstruction ( e.g. , peptic stricture ) must evaluate per standard care obstruction rule screening . Currently take opiate , expect use opiates course clinical trial . Currently take GLP1 agonist , SGLT2 inhibitor pramlintide . Allergic intolerant egg , wheat , milk , algae , component GEBT study meal . ( Glutenfree cracker provide . ) History anorexia nervosa , bingeeating , bulimia within 5 year screen . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 × upper limit normal ( ULN ) Visit 1 . History intestinal malabsorption pancreatic exocrine disease . Requires hemodialysis endstage renal disease . History human immunodeficiency virus ( HIV ) infection . Clinically significant neurologic psychiatric disorder likely impact compliance protocol requirement . Poor venous access inability tolerate venipuncture . Participation clinical study within 30 day prior dose present study . Any reason , Investigator 's opinion , would confound proper interpretation study expose patient unacceptable risk , include renal , hepatic cardiopulmonary disease , significant acute electrocardiogram ( ECG ) abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Delayed Gastric Emptying</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Gastroparesis</keyword>
	<keyword>Gastrointestinal Motility Disorder</keyword>
</DOC>